Our Platform

Our Platform

Rich, clinic-ready pipeline with multiple parallel programs

Our discovery platform has led to impactful therapies that change disease progression across several clinical modalities:

Pulmonary disease

Synedgen’s platform validation includes MIIST113 (SNSP113), now out-licensed to Synspira Inc. (Framingham, MA), and the lead asset is currently in Phase 2 clinical trials.

GI mucositis

Synedgen’s therapies provide relief from gastrointestinal side effects of cancer radiation therapy and are in early stages of product development.

Sinus care

Synedgen has completed pilot clinical trials for its sinus health product. This portfolio is being developed for acute and chronic rhinosinusitis.

Ophthalmic health

Synedgen has been awarded a 3 year grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to develop molecules intended to counteract severe, ulcerative eye injury.